$VTAE Wedbush Reiterates “Outperform” Rating for

New Post Public Reply Private Reply Replies (2) Message Board
fitzkarz
$VTAE

Wedbush Reiterates “Outperform” Rating for Vitae Pharmaceuticals Inc (VTAE)

Posted by paymon on Mar 7th, 2016 // No Comments

Vitae Pharmaceuticals logoVitae Pharmaceuticals Inc (NASDAQ:VTAE)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued to investors on Thursday, MarketBeat Ratings reports. They currently have a $20.00 price target on the stock. Wedbush’s price target suggests a potential upside of 326.44% from the stock’s current price.

VTAE has been the topic of a number of other research reports. Piper Jaffray reaffirmed a “buy” rating and set a $23.00 target price (up previously from $18.00) on shares of Vitae Pharmaceuticals in a report on Monday, January 4th. Zacks Investment Research downgraded Vitae Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 10th. Wells Fargo started coverage on Vitae Pharmaceuticals in a report on Thursday, December 3rd. They issued an “outperform” rating on the stock. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $22.00 price target on shares of Vitae Pharmaceuticals in a report on Wednesday, December 30th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $21.00.

Vitae Pharmaceuticals (NASDAQ:VTAE) opened at 4.69 on Thursday. Vitae Pharmaceuticals has a one year low of $4.15 and a one year high of $18.71. The company’s 50-day moving average price is $9.53 and its 200-day moving average price is $12.14. The firm’s market cap is $102.57 million.

Vitae Pharmaceuticals (NASDAQ:VTAE) last released its earnings results on Thursday, March 3rd. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.10. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.14 million. During the same period in the prior year, the business earned ($0.40) EPS. The company’s quarterly revenue was down 42.9% on a year-over-year basis. On average, analysts anticipate that Vitae Pharmaceuticals will post ($2.21) EPS for the current year.

A number of hedge funds have bought and sold shares of the stock. Ghost Tree Capital LLC boosted its stake in Vitae Pharmaceuticals by 10.0% in the fourth quarter. Ghost Tree Capital LLC now owns 275,000 shares of the company’s stock valued at $4,978,000 after buying an additional 25,000 shares in the last quarter. Boxer Capital LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $4,530,000. D. E. Shaw & Co. Inc. boosted its position in shares of Vitae Pharmaceuticals by 68.3% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 203,462 shares of the company’s stock valued at $3,683,000 after buying an additional 82,539 shares during the period. Millennium Management LLC boosted its position in shares of Vitae Pharmaceuticals by 15.2% in the fourth quarter. Millennium Management LLC now owns 873,436 shares of the company’s stock valued at $15,809,000 after buying an additional 114,981 shares during the period. Finally, Balyasny Asset Management LLC purchased a new position in shares of Vitae Pharmaceuticals during the fourth quarter valued at about $2,096,000.

In related news, CEO Jeffrey S. Hatfield sold 22,524 shares of the firm’s stock in a transaction that occurred on Wednesday, December 23rd. The stock was sold at an average price of $17.00, for a total value of $382,908.00. Following the sale, the chief executive officer now directly owns 293,897 shares in the company, valued at approximately $4,996,249. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Donald J. Hayden, Jr. sold 16,130 shares of the firm’s stock in a transaction that occurred on Tuesday, December 29th. The shares were sold at an average price of $18.00, for a total value of $290,340.00. The disclosure for this sale can be found here.

Vitae Pharmaceuticals, Inc is a clinical stage biotechnology company focused on discovering and developing small molecule drugs for diseases where there are unmet medical needs. The Company is developing a portfolio of product candidates generated by Contour, its structure-based drug discovery platform.
12 Month Chart for NASDAQ:VTAE

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!


Alway's searching for winners'
937206596_images.jpg
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 50

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Story Cannabis Bets on Neighborly Thanksgiving Outreach

Updated Category News Views 58

A frozen turkey is not a grand strategy deck, thank goodness; it is dinner for a household that might be feeling the squeeze. Story Cannabis plans to hand out 840 of them on Tuesday, Nov. 24, splitting the giveaway between Columbus and Cleveland with former Ohio State and Dallas Cowboys running back Michael Wiley joining employees and volunteers. In a cannabis business...

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 0

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Webster First Takes Aim at the Youth Money Literacy Gap

Updated Category News Views 39

Money mistakes get expensive long before anyone calls them mistakes. That is the uncomfortable point beneath Webster First Federal Credit Union CEO John Thomasian's November 20, 2026 discussion of financial literacy: plenty of young adults are entering the real financial world with a card, a loan offer, and a phone full of banking apps, but no sturdy framework for using...

Continue Reading
TOP-REAL Tests Digital Monitoring in HER2 Cancer Care

Updated Category News Views 116

A cancer treatment can be extraordinarily potent and still get derailed by what happens on an ordinary Tuesday at home. That unglamorous gap between clinic visits is the whole point of TOP-REAL, a phase II academic study presented at ESMO AI & Digital Oncology 2026. Solti and its European partners are testing whether closer digital follow-up can catch trouble early enough...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 55

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 13

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Arizona's Dry Climate Puts Scalp Health Under Stress

Updated Category News Views 65

Desert weather is unforgiving, and apparently the scalp does not get a pass. In a Nov. 20, 2026 discussion, Scottsdale and Tucson hair-restoration physician Dr. Sharon A. Keene frames Arizona hair concerns around something easy to overlook: the condition of the skin beneath the hair. That is a more sensible starting point than treating every strand in the shower like it...

Continue Reading

Top 5 Most Recently Viewed Articles

BlackBerry QNX and Pi Square Join Forces to Advance Indian Tech

Updated Category News Views 333

BlackBerry QNX Partners with Pi Square Technologies BlackBerry Limited (NYSE: BB) is experiencing a notable increase in share prices, reflecting growing investor confidence. Expanding Horizons for Engineers Recently, BlackBerry’s QNX division announced an exciting multi-year collaboration with Pi Square Technologies. This initiative aims to train thousands of engineers...

Continue Reading
Investors Urged to Act: Investigating DexCom Securities Claims

Updated Category News Views 67

Understanding the Ongoing Investigations into DexCom Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims on behalf of investors affected by losses in DexCom, Inc. (NASDAQ: DXCM). This inquiry is a direct response to significant concerns raised about the company's business practices and market performance. The Scope...

Continue Reading
Legal Battle Heats Up for Michigan Auto Attorney Over CURE

Updated Category News Views 299

Michigan Attorney Faces Legal Challenges Amid CURE Controversy In a recent turn of events, an attorney from Michigan is experiencing the challenges of navigating legal waters after speaking out against CURE Auto Insurance. The attorney, Steven M. Gursten, along with his firm Michigan Auto Law, is embroiled in lawsuits that highlight serious concerns about consumer...

Continue Reading
Investors of Joint Stock Company Kaspi.kz (KSPI) Take Action Now

Updated Category News Views 120

Investors of Joint Stock Company Kaspi.kz (NASDAQ: KSPI) Take Action Attention investors of Joint Stock Company Kaspi.kz, also known as KSPI! A recent report has raised serious concerns regarding the company's activities, prompting investors who have experienced losses to consider their options in filing a securities fraud lawsuit. These troubling developments are crucial...

Continue Reading
Investors Guide: Urgent Action Needed for Western Asset Fund

Updated Category News Views 130

Introduction to the Class Action The Rosen Law Firm, a prominent name in investor rights advocacy, is urging investors in the Western Asset Management Company mutual funds to take action before an important deadline. If you invested in the 'Western Asset US Core Bond Fund' or the 'Western Asset Core Plus Bond Fund' during the designated class period, this message is...

Continue Reading